Genekam making ready
for Nasdaq IPO 2024
The results of the above conference are as follows: 17 meetings were confirmed. 14 meetings with investment banks and investors took place. Now we have to do the follow up these meeting with investment banks and investors to see the final results.
Usually we are composed of 3 or 4 members coming from different scientific fields to create innovative solutions in the field of medicine. Here are experiences of some of our team members:
Member 1: Experience in virology, immunology and stem cells along with the field of management and marketing. Long experience in creating immunotherapies.
Member 2: Experience in Stemcells including cancer stem cells, fluorescent techniques like flow cytometry and molecular biology